Medicines manufacturing innovation centre
The Centre for Process Innovation (CPI), the University of Strathclyde, Scottish Enterprise, Innovate UK, AstraZeneca and GlaxoSmithKline (GSK) have partnered to open the Medicines Manufacturing Innovation Centre (MMIC) in Renfrewshire, Scotland.
Other pharmaceutical companies in the Medicines Manufacturing Industry Partnership (MMIP) are also involved in the project.
To be developed with an investment of £56m ($72.4m), the new innovation centre will allow pharmaceutical companies, research scientists and manufacturing partners to develop and test drug manufacturing technologies that incorporate productive, high-quality, sustainable and cost-effective practices. It will also address the key challenges faced by the pharmaceutical industry.
The project was launched in June 2018 and is currently in its design stage. The project will be completed in three years.
The MMIC will be built in the 52ha Advanced Manufacturing Innovation District Scotland (AMIDS) business park located in Inchinnan village next to Glasgow Airport. The AMIDS facility is a centre for research, innovation and advanced manufacturing.
Located adjacent to Lightweight Manufacturing Centre at Westway Business Park and the National Manufacturing Institute for Scotland (NMIS), the facility will support Scotland’s chemical and life sciences sectors.
The AMIDS centre offers approximately 150,000m² of floor space for life sciences, advanced manufacturing, aviation services, logistics resources and manufacturing solutions.
The MMIC will be equipped with advanced technical equipment and capabilities, which will allow scientists and companies to develop and manufacture small molecule medicines, fine chemicals, drug substances, and drug products in a good manufacturing practices (GMP) environment.
The facility will enable the adoption of next-generation technologies, reduce the quantity of materials used in process development and allow companies to release drugs in real-time, while reducing costs.
The facility will incorporate an array of advanced Industry 4.0 technologies to facilitate evaluation, testing and prototyping of processes through continuous, digital and autonomous manufacturing.
The project will also use continuous manufacturing techniques developed by the Continuous Manufacturing and Crystallisation Centre (CMAC) led by the University of Strathclyde for the development of drugs.
UK Research and Innovation is investing £13m ($16.7m) in the facility through the Industrial Strategy Challenge Fund (ISCF), while Scottish Enterprise is providing £15m ($19.3m). GSK and AstraZeneca are investing £7m ($9m) each.
The remaining investment will be made through revenue generated by funding bids and commercial projects.
Design and engineering firm BakerHicks was awarded a contract by CPI in January 2019 to provide architecture, design, pharmaceutical consultancy, civil and structural, mechanical and electrical, and process engineering to RIBA Stage 3.
The MMIC is expected to create 80 high-value jobs by 2023 and employ 90 people during its design and construction phases. It will also help generate indirect jobs through start-ups, and small, medium and large enterprises.
The facility is expected to draw an investment of £80.5m ($103.8m) in research and development (R&D) by 2028. It will deliver a substantial benefit to the pharmaceutical sector, which is a major contributor to Scotland’s economy.
The centre will also strengthen Scotland’s life sciences industry, which is expected to contribute up to £8bn ($10.3bn) to the Scottish economy by 2025.
Thermo Fisher Scientific (Thermo Fisher) will establish a new pharmaceutical services facility for integrated biologics and sterile drug development and…
Arranta Bio is constructing a new multi-product, commercial-ready manufacturing facility in Watertown, Massachusetts, US. Watertown facility will be used for…
Berkshire Sterile Manufacturing (BSM) is expanding its manufacturing facility in Lee, Massachusetts (MA), US. The company began preparations for the…
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…